Hikma Pharmaceuticals Release: AGM and Interim Management Statement
5/16/2013 10:17:08 AM
More...
|
Hikma Pharmaceuticals Signs Licensing and Marketing Agreement for Dance Biopharm's Inhaled Insulin in MENA
4/22/2013 10:46:54 AM
More...
|
Hikma Pharmaceuticals to Keep Injectable-Drug Unit After Completing Review
4/17/2013 8:55:09 AM
More...
|
Hikma Pharmaceuticals Delivers a Strong Performance in 2012 With Group Revenue Growth Up 21% and EPS Up 24%
3/13/2013 9:42:41 AM
More...
|
Hikma Pharmaceuticals Expands in Egypt With $22 Million Acquisition
1/10/2013 8:07:25 AM
More...
|
FDA Warning Hurts Hikma Pharmaceuticals Generics Margins
5/17/2012 8:05:36 AM
More...
|
AEterna Zentaris (AEZS) and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region
11/23/2011 6:56:29 AM
More...
|
Hikma Pharmaceuticals Enters the Moroccan Market Through the Acquisition of 63.9% of Promopharm for $111 Million
10/4/2011 6:35:13 AM
More...
|
Hikma Pharmaceuticals CEO Interviewed on Half-Year 2011 Results
8/25/2011 10:29:06 AM
More...
|
Hikma Pharmaceuticals Enhances its API Sourcing Capabilities Through a Strategic Partnership with the Chinese Pharmaceutical Company Hubei Haosun Pharmaceutical Co. Ltd.
7/11/2011 9:31:37 AM
More...
|
|